Welgene Biotech Co.,Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
November 07, 2023
Share
Welgene Biotech Co.,Ltd. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was TWD 80.43 million compared to TWD 72.2 million a year ago. Net loss was TWD 0.859 million compared to net income of TWD 4.71 million a year ago. Basic loss per share from continuing operations was TWD 0.04 compared to basic earnings per share from continuing operations of TWD 0.2 a year ago. Diluted loss per share from continuing operations was TWD 0.04 compared to diluted earnings per share from continuing operations of TWD 0.2 a year ago.
For the nine months, sales was TWD 206.89 million compared to TWD 249.62 million a year ago. Net income was TWD 0.095 million compared to TWD 12.11 million a year ago.
WELGENE BIOTECH CO., LTD. is a Taiwan-based company mainly engaged in the provision of genetic testing services and products. The company focuses on deoxyribonucleic acid (DNA) microarray, Next Generation Sequencing and real-time quantitative polymerase chain reaction (PCR) and other testing technologies, which used in school research units, hospitals and biotech companies. The Company is also engaged in the trading of medical equipment. The company mainly operates in two business segments, including Biotechnology Testing segment and Equipment Trading segment. The Company mainly operates in Taiwan market.